Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2, 2016. The report details a strategic regulatory milestone in GSK's respiratory therapy portfolio, specifically regarding a collaboration with Innoviva, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement rather than a financial results report.
Material Changes and Developments
- EU Regulatory Submission: GSK filed a Marketing Authorisation Application with the European Medicines Agency (EMA) for a once-daily closed triple combination therapy (fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Product Composition: The therapy combines an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta 2-adrenergic agonist (LABA) delivered via GSK's Ellipta dry powder inhaler.
- Global Pipeline: This follows a New Drug Application (NDA) submission in the US in November 2016. Regulatory submissions in other regions are anticipated to begin in 2017.
- Approval Status: The closed triple combination of FF/UMEC/VI is not currently approved for use anywhere in the world.
Outlook, Management Commentary, and Risks
Management Commentary: Dave Allen, Head of Respiratory Therapy Area Unit at GSK, emphasized the need for diverse treatment options for advanced COPD patients, noting that approval in Europe would complement GSK's portfolio of once-daily inhaled therapies. Mike Aguiar, CEO of Innoviva, described the EU filing as a significant development in their long-standing collaboration, potentially offering a meaningful addition to treatment options for advanced COPD.
Risks and Contingencies: The filing includes standard cautionary statements regarding forward-looking statements. Both GSK and Innoviva warn that actual results may differ materially from projections due to risks and uncertainties. GSK refers investors to the "Risk factors" section of its 2015 Annual Report on Form 20-F. Innoviva notes that development, regulatory, and commercial plans are subject to substantial risks and uncertainties as detailed in their SEC filings (Form 10-K and 10-Q).
Investor Verification Checklist
- Verify the current status of the EMA Marketing Authorisation Application for FF/UMEC/VI.
- Review the "Risk factors" in GSK's 2015 Form 20-F for specific regulatory and commercial risks.
- Monitor the timeline for regulatory submissions in regions outside the US and EU, anticipated to begin in 2017.
- Confirm the commercial terms and royalty structures between GSK and Innoviva regarding this specific asset.
- Assess the competitive landscape for once-daily triple combination therapies in the COPD market.